These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23551582)

  • 1. ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer.
    Neat MJ; Foot NJ; Hicks A; Breen R; Wilkins B; McLean E; Santis G
    Cytopathology; 2013 Dec; 24(6):356-64. PubMed ID: 23551582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple Gene Analysis Using Samples Obtained by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration.
    Lee K; Um SW; Jeong BH; Yang JW; Choi YL; Han J; Kim H; Kwon OJ
    Intern Med; 2016; 55(21):3105-3111. PubMed ID: 27803402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK translocation detection in non-small cell lung cancer cytological samples obtained by TBNA or EBUS-TBNA.
    Bravaccini S; Tumedei MM; Ulivi P; Zoli W; Calistri D; Candoli P; Amadori D; Puccetti M
    Cytopathology; 2016 Apr; 27(2):103-7. PubMed ID: 25757141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of EBUS-guided transbronchial needle aspiration for molecular testing in lung adenocarcinoma.
    Jurado J; Saqi A; Maxfield R; Newmark A; Lavelle M; Bacchetta M; Gorenstein L; Dovidio F; Ginsburg ME; Sonett J; Bulman W
    Ann Thorac Surg; 2013 Oct; 96(4):1196-1202. PubMed ID: 23972930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?
    Yarmus L; Akulian J; Gilbert C; Feller-Kopman D; Lee HJ; Zarogoulidis P; Lechtzin N; Ali SZ; Sathiyamoorthy V
    Ann Am Thorac Soc; 2013 Dec; 10(6):636-43. PubMed ID: 24079724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Testing for Targeted Therapy in Advanced Non-Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration.
    Casadio C; Guarize J; Donghi S; Di Tonno C; Fumagalli C; Vacirca D; Dell'Orto P; De Marinis F; Spaggiari L; Viale G; Barberis M
    Am J Clin Pathol; 2015 Oct; 144(4):629-34. PubMed ID: 26386084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.
    Rosenblum F; Hutchinson LM; Garver J; Woda B; Cosar E; Kurian EM
    Cancer Cytopathol; 2014 Nov; 122(11):810-21. PubMed ID: 25099128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
    Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
    Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G; Proietti A; Pelliccioni S; Niccoli C; Lupi C; Sensi E; Giannini R; Borrelli N; Menghi M; Chella A; Ribechini A; Cappuzzo F; Melfi F; Lucchi M; Mussi A; Fontanini G
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adequacy of EBUS-TBNA specimen for mutation analysis of lung cancer.
    Cicek T; Ozturk A; Yılmaz A; Aktas Z; Demirag F; Akyurek N
    Clin Respir J; 2019 Feb; 13(2):92-97. PubMed ID: 30582673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.
    Ilie MI; Bence C; Hofman V; Long-Mira E; Butori C; Bouhlel L; Lalvée S; Mouroux J; Poudenx M; Otto J; Marquette CH; Hofman P
    Ann Oncol; 2015 Jan; 26(1):238-244. PubMed ID: 25344360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
    Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anaplastic lymphoma kinase-positive adenocarcinoma of lung: a cytopathologic analysis].
    Chen Y; Gao L; Wang Y; Gui X; Zhang H; Wang L; Gu L; Feng L; Wu J; Yang W; Song Y; Zeng H; Zhang J; Bai Q; Zhou X; Ping B
    Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):628-32. PubMed ID: 26705277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity.
    Kimura H; Nakajima T; Takeuchi K; Soda M; Mano H; Iizasa T; Matsui Y; Yoshino M; Shingyoji M; Itakura M; Itami M; Ikebe D; Yokoi S; Kageyama H; Ohira M; Nakagawara A
    Lung Cancer; 2012 Jan; 75(1):66-72. PubMed ID: 21757253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.
    Wang J; Cai Y; Dong Y; Nong J; Zhou L; Liu G; Su D; Li X; Wu S; Chen X; Qin N; Zeng X; Zhang H; Zhang Z; Zhang S
    PLoS One; 2014; 9(7):e101551. PubMed ID: 24992725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues.
    Zhang YG; Jin ML; Li L; Zhao HY; Zeng X; Jiang L; Wei P; Diao XL; Li X; Cao Q; Tian XX
    PLoS One; 2013; 8(5):e64821. PubMed ID: 23741400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.